in the United States, with nearly 250 000 deaths attributed to ALD in 2010. 2, 3 Overall US clinical burden of ALD remains unclear, perhaps because of lack of a definitive standard for identifying ALD. This study focused on the specific, more well-defined subset of AFLD to estimate national prevalence among US adults. Multivariable logistic regression with appropriate sample weights was used to derive AFLD prevalence. Linear trends in prevalence were analyzed using orthogonal polynomial contrasts. Interaction terms were included in logistic regression models to assess whether prevalence changes differed by sex, age, and race/ethnicity. Missing data, ranging from less than 1% to 15%, were addressed using multivariable imputation by chained equations, which included relevant demographic and clinical covariates. Two-tailed P < .05 indicated statistical significance (Stata version 14.0 [StataCorp] ). The Alameda Health System institutional review board granted exempt status and waiver of informed consent.
Results | Among 34 423 respondents included, 4.3% were identified with AFLD (60.6% men; 63.0% non-Hispanic white; mean age, 40.2 years). From 2001-2002 to 2015-2016, AFLD prevalence remained stable from 4.3% (95% CI, 3.5%-5.0%) to 4.7% (95% CI, 4.2%-5.1%) (P = .69), AFLD with stage 2 or greater fibrosis increased from 0.6% (95% CI, 0.5%-0.8%) to 1.5% (95% CI, 1.3%-1.8%) (P < .001), and AFLD with stage 3 or greater fibrosis increased from 0.1% (95% CI, 0.02%-0.10%) to 0.2% (95% CI, 0.2%-0.4%) (P = .045) (Figure) . Changes in prevalence over time did not differ by sex, age, or race/ethnicity, and no significant interactions were observed across all variables (Table) .
Discussion | The prevalence of AFLD among US adults remained stable from 2001 to 2016, affecting 4.7% of adults in 2015-2016. However, the prevalence of AFLD with stage 2 or greater fibrosis and AFLD with stage 3 or greater fibrosis increased significantly, affecting 1.5% and 0.2% of adults, respectively, in 2015-2016. This is a particularly concerning observation given that developing fibrosis is the strongest predictor of progression to cirrhosis, liver cancer, and death. Limitations include the challenges in accurately identifying AFLD using observational data, which may have been affected by misclassification. Noninvasive serologic markers of fibrosis used in this study are well validated, but not specifically for AFLD. The increasing prevalence of US adults with AFLD with stage 2 or greater fibrosis and AFLD with stage 3 or greater fibrosis is concerning and emphasizes the need for greater awareness of unhealthy alcohol use and need for early prevention and intervention efforts. 
COMMENT & RESPONSE Prophylactic Hypothermia for Severe Traumatic Brain Injury
To the Editor In a multicenter randomized clinical trial, Dr Cooper and colleagues reported that early prophylactic hypothermia (33-35°C) compared with active normothermia did not improve neurologic outcome at 6 months after severe traumatic brain injury (TBI). 1 However, we believe that the study had some limitations that preclude definite conclusions. The objective of brain resuscitation is intracranial pressure control, but cerebral blood flow or cerebral oxygenation (eg, by transcranial Doppler or brain tissue oxygen partial pressure monitoring) were not reported in the study. Hence, patients may have experienced silent decreased brain oxygenation.
In addition, PaCO 2 values were similar in both groups, and there was no effect of hypothermia on intracranial pressure. Therefore, PaCO 2 was managed according to the pH-stat principle, which means that relative hypocapnia induced by hypothermia was balanced by changing the respirator settings (ie, decreasing minute volume). However, to make therapeutic hypothermia effective in the management of intracranial pressure, relative hypocapnia must be tolerated (alpha-stat principle). 2 Under these conditions, the decline in cerebral blood flow is compensated by the concomitant decrease in brain metabolism, which is measured by the stability of the cerebral oxygenation indexes. 2 In contrast, permissive hypercapnia (pH-stat management) is acceptable only in the case of low intracranial pressure, as is often observed after resuscitated cardiac arrest. We believe that management of PaCO 2 is decisive for hypothermia after severe TBI and needs to be adapted to the primary study objective. If the aim is control of intracranial pressure, alpha-stat management should be prioritized while monitoring cerebral oxygenation to avoid low cerebral blood flow. If the aim is neuroprotection, pH-stat management is preferable but requires intracranial pressure monitoring because there is a risk of relative hypercapnia.
Three other randomized trials assessed effect of hypothermia after severe TBI. The NABIS:HII study failed to show a neuroprotective effect of hypothermia 3 with management of PaCO 2 according to the alpha-stat principle. The Eurotherm3235 study did not demonstrate a positive effect of hypothermia on the control of intracranial hypertension during which the management of PaCO 2 followed the pH-stat principle. 4 None of these studies thus fully corresponded to the above criteria. Only in the B-HYPO study was PaCO 2 managed correctly for assessing neuroprotective effect (pH-stat principle), with negative results that need confirmation.
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In summary, management of PaCO 2 and adapted monitoring are key issues for the success or failure of studies of hypothermia after severe TBI.
Nicolas Engrand, MD Alexandre Pharaboz, MD Vera Dinkelacker, MD, PhD
